MedTrace Logo

Paclitaxel-Avelumab for Angiosarcoma

NCT03512834 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-07-11

No results posted yet for this study

Summary

To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first line treatment for the patients with inoperable angiosarcoma.

Conditions

  • Angiosarcoma Metastatic

Interventions

DRUG

Avelumab

Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity

DRUG

Paclitaxel

Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    collaborator INDUSTRY

  • Sung Yong Oh

    lead OTHER

Principal Investigators

  • SUNG YONG OH, MD · Dong-A University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2022-11-30
Completion
2023-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03512834 on ClinicalTrials.gov